Table 1.
Immunohistochemistry for HIF-1α in clinical samples of PML
| No. | Age (years) |
Gender | Diagnosis | Associated | Immunohistochemistry |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oligodendrocytes |
Astrocytes |
|||||||||
| VP-1 | Agno | HIF-1α | VP-1 | Agno | HIF-1α | |||||
| 1 | 73 | Female | Non-AIDS-PML | Renal Transplant | ++n | ++cy | +++n | ++n/+cy | ++cy | +++n/cy |
| 2 | 46 | Male | Non-AIDS-PML | Lymphocytic Leukemia | +++n | +cy | +++n | ++n | +cy | ++n/cy |
| 3 | 31 | Female | AIDS-PML | AIDS | +++n/++cy | +++cy | ++n | ++n | ++cy | ++cy |
| 4 | 36 | Male | AIDS-PML | AIDS | +++n | ++cy | ++++n | ++n/+cy | ++cy | +cy |
| 5 | 37 | Male | AIDS-PML | AIDS | +++n | +++cy | +++n | +++n | ++cy | ++n/cy |
| 6 | 48 | Female | AIDS-PML | AIDS | +++n | ++cy | +n | ++n/+cy | +++cy | ++n/cy |
| 7 | 44 | Male | AIDS-PML | AIDS | +++n/+cy | +cy | ++n | ++n/+cy | ++cy | ++n/cy |
| 8 | 38 | Male | AIDS-PML | AIDS | ++n | +cy | ++n | ++n | +cy | +cy |
| 9 | 35 | Female | AIDS-PML | AIDS | ++n | ++cy | +++n/+cy | ++n/+cy | +cy | ++n/cy |
| 10 | 52 | Male | AIDS-PML | AIDS | +++n/++cy | +++cy | ++n | +++n/++cy | ++cy | ++cy |
| 11 | 42 | Male | Normal Brain | Myocradial Infarction | − | − | − | − | − | +weak cy |
| 12 | 62 | Female | Normal Brain | Renal Failure | − | − | − | − | − | − |
AIDS Acquired Immuno Deficiency Syndrome, PML Progressive Multifocal Leukoencephalopathy, VP-1 JCV Capsid Protein VP1, Agno JCV Late Product Agnoprotein, n nuclear, cy cytoplasmic, − negative, + weak immunoreactivity, ++ moderate immunoreactivity, +++ robust immunoreactivity